Who Paid My Doc
Daniel Gelfond
Pediatric Gastroenterology Batavia, NY Medical Doctor
NPI 1033200191 CMS profile 1803
166 Washington Ave, Batavia, NY 14020
General payments
$30,107
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$32,235
Through program year 2025, Daniel Gelfond of Batavia, NY is reported in the CMS Open Payments database as having received $30,107 across 374 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $32,235 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 94th percentile of Pediatric Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,277 | 67 | |
| 2024 | General | $1,061 | 53 | |
| 2023 | General | $1,171 | 67 | |
| 2022 | General | $8,097 | 55 | |
| 2021 | General | $1,081 | 71 | |
| 2020 | General | $6,255 | 31 | |
| 2019 | General | $11,166 | 30 |
Beside peers
- Daniel Gelfond
- Pediatric Gastroenterology median
- Middle half of Pediatric Gastroenterology
- National median
In program year 2025, general payments to Daniel Gelfond were reported at $1,277. Among 1,132 Pediatric Gastroenterology profiles paid that year, the median was $194 and the middle half received between $81 and $540.
Show as a table
| Year | Daniel Gelfond | Pediatric Gastroenterology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $11,166 | $131 | $41–$311 | $163 |
| 2020 | $6,255 | $79 | $23–$223 | $114 |
| 2021 | $1,081 | $104 | $32–$321 | $132 |
| 2022 | $8,097 | $125 | $37–$331 | $149 |
| 2023 | $1,171 | $169 | $55–$440 | $160 |
| 2024 | $1,061 | $196 | $73–$563 | $164 |
| 2025 | $1,277 | $194 | $81–$540 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
374 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Gastroenterology in New York
Sivan Kinberg
Pediatric Gastroenterology · New York, NY
Tuvia Marciano
Pediatric Gastroenterology · Mineola, NY
Mirna Chehade
Pediatric Gastroenterology · New York, NY
Michael Dolinger
Pediatric Gastroenterology · New York, NY
Thomas Wallach
Pediatric Gastroenterology · New York, NY
Neal Leleiko
Pediatric Gastroenterology · New York, NY
Related records
Pediatric Gastroenterology in New York
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Gastroenterology
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.